These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

100 related items for PubMed ID: 2859415

  • 1. Normal MPTP binding in parkinsonian substantial nigra: evidence for extraneuronal toxin conversion in human brain.
    Uhl GR, Javitch JA, Snyder SH.
    Lancet; 1985 Apr 27; 1(8435):956-7. PubMed ID: 2859415
    [Abstract] [Full Text] [Related]

  • 2. Similar distribution of monoamine oxidase (MAO) and parkinsonian toxin (MPTP) binding sites in human brain.
    Reznikoff G, Manaker S, Parsons B, Rhodes CH, Rainbow TC.
    Neurology; 1985 Oct 27; 35(10):1415-9. PubMed ID: 3875804
    [Abstract] [Full Text] [Related]

  • 3. Selectivity of the parkinsonian neurotoxin MPTP: toxic metabolite MPP+ binds to neuromelanin.
    D'Amato RJ, Lipman ZP, Snyder SH.
    Science; 1986 Feb 28; 231(4741):987-9. PubMed ID: 3080808
    [Abstract] [Full Text] [Related]

  • 4. Biochemical mechanism of action of the dopaminergic neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP).
    Sayre LM.
    Toxicol Lett; 1989 Aug 28; 48(2):121-49. PubMed ID: 2672418
    [Abstract] [Full Text] [Related]

  • 5. [Significance of the neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine for the etiology and therapy of idiopathic Parkinson disease].
    Lange KW.
    Fortschr Neurol Psychiatr; 1989 Apr 28; 57(4):142-8. PubMed ID: 2656447
    [Abstract] [Full Text] [Related]

  • 6. Localization in rat brain of binding sites for parkinsonian toxin MPTP: similarities with [3H]pargyline binding to monoamine oxidase.
    Rainbow TC, Parsons B, Wieczorek CM, Manaker S.
    Brain Res; 1985 Mar 25; 330(2):337-42. PubMed ID: 3872699
    [Abstract] [Full Text] [Related]

  • 7. Parkinsonism-inducing neurotoxin, N-methyl-4-phenyl-1,2,3,6 -tetrahydropyridine: uptake of the metabolite N-methyl-4-phenylpyridine by dopamine neurons explains selective toxicity.
    Javitch JA, D'Amato RJ, Strittmatter SM, Snyder SH.
    Proc Natl Acad Sci U S A; 1985 Apr 25; 82(7):2173-7. PubMed ID: 3872460
    [Abstract] [Full Text] [Related]

  • 8. The actions of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in animals as a model of Parkinson's disease.
    Jenner P, Marsden CD.
    J Neural Transm Suppl; 1986 Apr 25; 20():11-39. PubMed ID: 3091760
    [Abstract] [Full Text] [Related]

  • 9. Parkinsonism-inducing neurotoxin, N-methyl-4-phenyl-1,2,3,6 -tetrahydropyridine: characterization and localization of receptor binding sites in rat and human brain.
    Javitch JA, Uhl GR, Snyder SH.
    Proc Natl Acad Sci U S A; 1984 Jul 25; 81(14):4591-5. PubMed ID: 6611553
    [Abstract] [Full Text] [Related]

  • 10. Autoradiography of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP): uptake in the monoaminergic pathways and in melanin containing tissues.
    Lydén A, Bondesson U, Larsson BS, Lindquist NG, Olsson LI.
    Acta Pharmacol Toxicol (Copenh); 1985 Aug 25; 57(2):130-5. PubMed ID: 3877403
    [Abstract] [Full Text] [Related]

  • 11. Characterization of the binding of N-methyl-4-phenylpyridine, the toxic metabolite of the parkinsonian neurotoxin N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine, to neuromelanin.
    D'Amato RJ, Benham DF, Snyder SH.
    J Neurochem; 1987 Feb 25; 48(2):653-8. PubMed ID: 3491879
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. The significance of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine.
    Marsden CD, Jenner PG.
    Ciba Found Symp; 1987 Feb 25; 126():239-56. PubMed ID: 3556086
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. MPTP: a neurotoxin relevant to the pathophysiology of Parkinson's disease. The 1985 George C. Cotzias lecture.
    Snyder SH, D'Amato RJ.
    Neurology; 1986 Feb 25; 36(2):250-8. PubMed ID: 3080696
    [Abstract] [Full Text] [Related]

  • 17. The clinical syndrome of striatal dopamine deficiency. Parkinsonism induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP).
    Burns RS, LeWitt PA, Ebert MH, Pakkenberg H, Kopin IJ.
    N Engl J Med; 1985 May 30; 312(22):1418-21. PubMed ID: 2581135
    [Abstract] [Full Text] [Related]

  • 18. Distribution of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in experimental animals studied by postiron emission tomography and whole body autoradiography.
    Hartvig P, Lindquist NG, Aquilonius SM, d'Argy R, Bergström K, Bondesson U, Eckernäs SA, Gullberg P, Larsson BS, Lindberg B.
    Life Sci; 1986 Jan 06; 38(1):89-97. PubMed ID: 3484535
    [Abstract] [Full Text] [Related]

  • 19. Permanent human parkinsonism due to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP): seven cases.
    Ballard PA, Tetrud JW, Langston JW.
    Neurology; 1985 Jul 06; 35(7):949-56. PubMed ID: 3874373
    [Abstract] [Full Text] [Related]

  • 20. Metallobiology of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine neurotoxicity.
    Hare DJ, Adlard PA, Doble PA, Finkelstein DI.
    Metallomics; 2013 Feb 06; 5(2):91-109. PubMed ID: 23322189
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 5.